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Introduction
Systemic Juvenile Idiopathic Arthritis (sJIA) is chronic
disease. Some patients are resistant to standard immuno-
supressivetherapy and anti IL6 treatment. Some of these
patients have autoinflammatory disease.
Case Report
The patient became ill when she was 3 years old. She had
fever, rash and artralgia and pericarditis. After examina-
tion in hospital she was diagnosed sJIA. She took gluco-
corticosteroids 1 mg/kg daily per os, methylprednisolone
10 mg/kg IV, №3, and MTX 10mg/m2/week with positive
results. She took that therapy during 2 years. When the
dose of GC decreased she had flares (fever, rash, arthritis).
In 2 years after beginning she was examined for TRAPS.
She took infliximab without improving. The analysis for
TRAPS was negative. When she took GC 0,5 mg/kg/day
she had sever flare and tocilizumab treatment was
initiated. The fever disappeared and CRP was normal but
rash was persisted. She took tocilizumab 10 months and
dose of GC was decreased to 0,05 mg/kg/day. After
10 months of tocilizumab treatment she had toxic allergic
reaction and tocilizumab was canceled. She was examined
for CAPS and mutation in gene NLRP3 - c.2113C>A in
geterozygota. In that time there was no anti IL-1 medi-
cines in Russia so she was given cyclosporine and MTX
was continued. When she was 7 years old for flare canaci-
numab therapy was initiated in dose 4 mg/kg. The fever,
rash, arthritis were disappeared and CRP and ESR became
normal. After 3 months GC was cancelled. After 4 canaci-
numab injection she had flare and puls therapy of GC IV
was performed with positive results.
Discussion
So it is still question if she has CAPS or sJIA. Because She
is not in remission on anti IL 1 therapy and also GC
therapy is effective for this patient and on the other hand
she has mutation in the cryopirin gene.
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